1169956-08-4
1169956-08-4
Chemical Structure
Ocaratuzumab
Synonym(s): AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody
- CAS No.: 1169956-08-4
- Formula:N/A
- Molecular Weight:(145.38 kDa)
IUPAC Name: 2-bromo-6,8-dimethoxyindolizine
SMILES: [Ocaratuzumab]
Biological Activity: Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ocaratuzumab | 95.00% | Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Forero-Torres A, et, al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403. [Content Brief]
- [2]. Cheney CM, et, al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs. 2014 May-Jun;6(3):749-55. [Content Brief]
